TAR RNA was custom synthesized (Dharmacon, Austria), H2O was purified to 18 MΩŊcm at room temperature using a Milli-Q system (Millipore, Austria), CH3OH (Acros, Austria) was HPLC-grade, and ammonium acetate ("for mass spectrometry") and piperidine (>99.5%) were purchased from Sigma-Aldrich (Austria). For desalting, 500 µl RNA solution (up to 20 µM) was concentrated to 100 µl using Vivaspin 500 centrifugal concentrators (Sartorius, Austria, PES membrane, MWCO 5000), and 400 µl ammonium acetate solution (100 mM) was added. The process was repeated five times, followed by six cycles of concentration and dilution with H2O. The 12-residue tat peptide (residues 48-57 of tat protein) was purchased from Sigma-Aldrich (Austria), and used without further purification.
Prior to each experiment, desalted TAR RNA solution (10-15 µM in H2O) was heated to 90 ºC for 90 s, followed by cooling on ice for 10 min and thermal equilibration for another 10 min at room temperature. Solutions for ESI (flow rate 1.5 µl/min) were prepared by diluting TAR RNA and tat peptide stock solutions to a final concentration of 2 µM each in 9:1 vol H2O/CH3OH with piperidine as additive (750 µM -2 mM). Between 10 and 50 (ESI) or 100 and 500 (CAD) scans were added for each spectrum, and data reduction utilized the SNAP2 algorithm (Bruker, Austria) . Mass values of molecular (ESI) or fragment (CAD) ions without peptide attached were used for internal calibration of the spectra (standard deviation <0.5 ppm, see Tables S1 and S2 ).
Time-resolved ESI MS of TAR-tat complexes
For time-resolved experiments ( Figure S1c ), ESI was operated in either "offline" or "online" mode. In offline-ESI experiments, solution was prepared, loaded into a syringe that was connected by PEEK tubing to the sample inlet of the ESI-source (Apollo II, Bruker), and the spray started by turning on the syringe pump at a flow rate of 1.5 µl/min. Up to 4 spectra were recorded in less than 4 minutes before disconnecting the syringe and thoroughly rinsing all parts with solvent (9:1 H2O/CH3OH at pH 7.7, adjusted by addition of piperidine). For online-ESI, solution was prepared, loaded into the syringe, and continuously sprayed for up to 80 min, during which spectra were recorded in 5 min intervals.
Calculation of fragment yields
Fragment yields were calculated as %-values of the sum of all ion abundances, considering that RNA backbone cleavage gives a pair of complementary c and y or a and w ions, and taking into account that the formation of internal fragments requires two backbone cleavages: 100% = 0. Figure S2 . Yield of c, y, a, w, and i fragments (left axis) and yield of undissociated ions and sequence coverage (right axis) from CAD of a) (TAR-14H) 14-, b) (TAR+tat-13H) 13-, c) (TAR+2tat-12H) 12-ions versus laboratory frame energy (bottom axis); lines are meant to guide the eye. Three major factors contribute to differences in energy required for dissociation of (TAR-14H) 14-, (TAR+tat-13H) 13-, and (TAR+2tat-12H) 12-ions. First, each tat added to TAR increases the number of vibrational degrees of freedom over which energy is distributed, second, a decrease in ion net charge generally increases the energy required for dissociation, and third, ion structure and intramolecular charge distribution play a role. Because the exact contributions of these factors cannot be quantified, we used energies that produced the same extent of dissociation (36%) for assignment of binding sites in 1:1 and 1:2 TAR-tat complexes in Figure 3 . Figure S3 . Yield of c and y fragments from CAD of (TAR-14H) 14-ions (without tat peptide attached, 0 tat) at 84 eV laboratory frame energy (32% dissociation). Figure S4 . Average charge nav of a) c and b) y fragments with and without tat from CAD of (TAR+tat-13H) 13-ions at 120.9 eV laboratory frame energy versus cleavage site. Figure S5 . As in Figures 2c and 2d , yield of c and y ions from CAD of (TAR+tat-13H) 13-, and level of occupancy with tat peptide vs. laboratory frame energy for cleavage at sites 6 (a) and 10-14 (b-f). Figure S5 continued. yield of c and y ions from CAD of (TAR+tat-13H) 13-, and level of occupancy with tat peptide vs. laboratory frame energy for cleavage at sites 15-17 (g-i) and 19-21 (j-l). Figure S6 . a) CAD spectrum of (TAR+2tat-12H) 12-ions at 154.8 eV laboratory frame energy (36% dissociation), with c(0 tat) and y(0 tat) fragments labeled in black, c(1 tat) and y(1 tat) in blue, and c(2 tat) and y(2 tat) in violet; b) yield of c and y fragments without (0 tat), with one (1 tat), and with two (2 tat) peptides attached; c) and d) level of occupancy of c (r, left axis) and y (s, right axis) fragments with tat peptides as indicated. Figure S7 . As in Figures 2c and 2d , yield of c and y ions from CAD of (TAR+2tat-12H) 12-, and level of occupancy with tat peptide vs. laboratory frame energy for cleavage at sites 3 (a) and 6-10 (b-f). Figure S7 continued. yield of c and y ions from CAD of (TAR+2tat-12H) 12-, and level of occupancy with tat peptide vs. laboratory frame energy for cleavage at sites 11-16 (g-l) . 
